Momelotinib, a novel oral ACVR1/ALK2 and JAK1/2 inhibitor, showed superior efficacy compared with danazol in myelofibrosis patients previously treated with a Janus kinase (JAK) inhibitor, according to results presented at the European Hematology Association 2022 Congress (abstract S195).
The data come from the pivotal phase 3 MOMENTUM trial, in which post–essential thrombocythemia and post–polycythemia vera myelofibrosis patients previously treated with JAK inhibitors were randomly